Small cell lung cancer : The role of haematopoietic growth factors /

por Hansen, H H, Kristjanesen, Peg
Publicado em 1990.

Letter: Forecasting subarachnoid haemorrhage.

por Olivarius, B D, Buhl, M, Hansen, H H
Publicado em 1975

Performance status assessment in cancer patients. An inter-observer variability study.

por Sørensen, J. B., Klee, M., Palshof, T., Hansen, H. H.
Publicado em 1993

Response to cytostatic treatment in inoperable adenocarcinoma of the lung: critical implications.

por Sørensen, J. B., Badsberg, J. H., Hansen, H. H.
Publicado em 1989

Treatment policy of surgery in small cell carcinoma of the lung: retrospective analysis of a series of 874 consecutive patients.

por Osterlind, K, Hansen, M, Hansen, H H, Dombernowsky, P, Rørth, M
Publicado em 1985

Serum neuron specific enolase (NSE) is a determinant of response duration in small cell lung cancer (SCLC).

por Jørgensen, L. G., Osterlind, K., Hansen, H. H., Cooper, E. H.
Publicado em 1992

Serum neuron-specific enolase (S-NSE) in progressive small-cell lung cancer (SCLC).

por Jørgensen, L. G., Osterlind, K., Hansen, H. H., Cooper, E. H.
Publicado em 1994

The prognostic influence of serum neuron specific enolase in small cell lung cancer.

por Jørgensen, L. G., Osterlind, K., Hansen, H. H., Cooper, E. H.
Publicado em 1988

The Variability of Individual Tolerance to Methotrexate in Cancer Patients

por Hansen, H. H., Selawry, O. S., Holland, J. F., McCall, C. B.
Publicado em 1971

Methotrexate in Liver and Bile after Intravenous Dosage in Man

por Creaven, P. J., Hansen, H. H., Alford, D. A., Allen, L. M.
Publicado em 1973

Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?

por Gronlund, B, Hansen, H H, Høgdall, C, Høgdall, E V S, Engelholm, S A
Publicado em 2004

Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.

por Jensen, P. B., Christensen, I. J., Sehested, M., Hansen, H. H., Vindeløv, L.
Publicado em 1993

Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer. Results of a controlled trial with 5 years follow-up.

por Osterlind, K., Hansen, H. H., Hansen, H. S., Dombernowsky, P., Hansen, M., Rørth, M.
Publicado em 1986

Severe intracellular magnesium and potassium depletion in patients after treatment with cisplatin

por Lajer, H, Bundgaard, H, Secher, N H, Hansen, H H, Kjeldsen, K, Daugaard, G
Publicado em 2003

Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression

por Lassen, U N, Østerlind, K, Hirsch, F R, Bergman, B, Dombernowsky, P, Hansen, H H
Publicado em 1999

Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer

por Sørensen, J B, Bergman, B, Nielsen, A L, Krarup, M, Dombernowsky, P, Hansen, H H
Publicado em 1999

In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL).

por Jensen, P. B., Vindeløv, L., Roed, H., Demant, E. J., Sehested, M., Skovsgaard, T., Hansen, H. H.
Publicado em 1989

The clinical and screening age-at-onset distribution for the MEN-2 syndrome.

por Easton, D F, Ponder, M A, Cummings, T, Gagel, R F, Hansen, H H, Reichlin, S, Tashjian, A H, Telenius-Berg, M, Ponder, B A
Publicado em 1989